IBA Launches AdaPTinsight XR to Boost Proton Therapy Imaging Precision
Event summary
- IBA introduced AdaPTinsight XR, an advanced CBCT imaging solution for proton therapy, on May 13, 2026.
- The new system enhances image quality with improved contrast resolution, artifact suppression, and calibration.
- AdaPTinsight XR is designed to support faster patient positioning and more confident clinical decisions.
- IBA will showcase the technology at the ESTRO 2026 Annual Congress in Stockholm from May 15–18, 2026.
The big picture
IBA’s AdaPTinsight XR reinforces its leadership in proton therapy by addressing a critical need for higher precision in image-guided treatments. As proton therapy gains traction as a preferred cancer treatment, advancements in imaging technology like this could accelerate its adoption, particularly in complex cases requiring soft-tissue visualization. The upgrade path for existing systems also positions IBA to maintain its market share in a competitive landscape.
What we're watching
- Adoption Pace
- How quickly existing Proteus® systems will upgrade to AdaPTinsight XR, given its upgradeability focus.
- Clinical Impact
- Whether the improved imaging capabilities will lead to measurable improvements in treatment outcomes.
- Market Expansion
- The extent to which this technology will help proton therapy become the standard of care for more cancer indications.
Related topics